Tevogen Inc. (TVGN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Tevogen Inc., a healthcare company focused on biotechnology (Tevogen Bio), artificial intelligence (Tevogen.AI), and healthcare services. The reporting period covers the three and six months ended June 30, 2026. The company is a smaller reporting company and an emerging growth company. It operates as a single segment focused on the development of off-the-shelf cellular immunotherapies, specifically its lead candidate TVGN 489 for COVID-19.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | As of June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(5.76) million | $(11.21) million | N/A |
| Net Loss Per Share (Basic & Diluted) | $(1.52) | $(3.16) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1.08 million |
| Total Assets | N/A | N/A | $4.73 million |
| Total Liabilities | N/A | N/A | $13.62 million |
| Stockholders' Deficit | N/A | N/A | $(8.89) million |
| Debt (Loan Agreement) | N/A | N/A | $6.40 million outstanding |
| Notes Payable (Defaulted) | N/A | N/A | $1.65 million |
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss for the six months ended June 30, 2026, decreased to $11.21 million from $15.87 million in the same period in 2025. This improvement was primarily driven by a significant reduction in stock-based compensation expense ($6.14 million in 2026 vs. $10.53 million in 2025) and lower legal/professional fees.
- Operating Expenses: Total operating expenses decreased to $11.06 million for the six months ended June 30, 2026, compared to $15.80 million in the prior year period. Research and Development (R&D) expenses increased slightly to $6.42 million due to higher stock-based compensation, while General and Administrative (G&A) expenses dropped significantly to $4.65 million.
- Liquidity Position: Cash increased from $0.55 million at December 31, 2025, to $1.08 million at June 30, 2026, driven by financing activities including a $3.0 million PIPE transaction (pre-funded warrants) and $2.0 million drawn from the Loan Agreement.
- Capital Structure: The company completed a 1-for-50 reverse stock split effective March 6, 2026. Additionally, $1.30 million was raised under the At-The-Market (ATM) sales agreement during the period.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management believes current cash ($1.08 million), combined with $11.0 million available under the Loan Agreement and a committed $7.0 million grant from KRHP, is sufficient to fund operations for at least the next 12 months. The company does not plan to initiate new clinical trials until additional funding is secured.
- Nasdaq Compliance Risk: The company received notice from Nasdaq in April 2026 that it failed to meet the minimum market value of listed securities ($50 million) and minimum market value of publicly held shares ($15 million) requirements. The company has until October 2026 to regain compliance or face potential delisting.
- Debt Default: The company is in default on $1.65 million of notes payable assumed from the Merger, which were due within five business days of the merger closing. However, the default provisions do not currently require immediate transfer of shares or cash payments.
- Stock-Based Compensation: A significant portion of operating expenses is non-cash stock-based compensation. Unrecognized compensation cost related to service-based awards is approximately $78.9 million, to be expensed over a weighted average of 7.7 years.
- Subsequent Events: In July 2026, the company granted 2.25 million shares of Restricted Stock to executives and employees with a total grant date fair value of $11.08 million.
Investor Verification Checklist
- Nasdaq Compliance Status: Verify if the company has regained compliance with Nasdaq listing requirements (MVLS and MVPHS) by the October 2026 deadlines to avoid delisting.
- Debt Default Resolution: Confirm the status of the $1.65 million defaulted notes payable and whether any enforcement actions have been initiated by the holder (Polar Multi-Strategy Master Fund).
- Grant Funding Reliability: Assess the certainty of the remaining $7.0 million grant commitment from KRHP, a related party, as this is critical to the 12-month liquidity runway.
- Loan Agreement Terms: Review the terms of the $36 million Loan Agreement with the Patel Family, specifically the purchase options exercisable if the stock price reaches $500 (post-split), which could lead to significant dilution.
- Stock-Based Compensation Runway: Evaluate the impact of the $78.9 million in unrecognized stock-based compensation on future earnings and cash flow projections.